Holen Sie sich die Stockscreener-App
83.78
4.34%
-4.255
Schlusskurs vom Vortag:
$88.03
Offen:
$86.33
24-Stunden-Volumen:
720.81K
Relative Volume:
0.37
Marktkapitalisierung:
$11.02B
Einnahmen:
$902.57M
Nettoeinkommen (Verlust:
$-398.79M
KGV:
-26.07
EPS:
-3.2131
Netto-Cashflow:
$-274.52M
1W Leistung:
-9.04%
1M Leistung:
-18.05%
6M Leistung:
+53.40%
1J Leistung:
+95.38%
1-Tages-Spanne:
$83.83
$87.21
1-Wochen-Bereich:
$83.83
$93.00
52-Wochen-Spanne:
$36.36
$120.74
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
84.00 | 11.55B | 902.57M | -398.79M | -274.52M | -3.2131 |
|
TMO
Thermo Fisher Scientific Inc
|
477.33 | 184.15B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
188.50 | 137.93B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
582.23 | 47.82B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.87 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
287.80 | 29.19B | 3.17B | 642.63M | 516.49M | 10.77 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Bestätigt | Canaccord Genuity | Buy |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-09-25 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-28 | Fortgesetzt | BTIG Research | Buy |
| 2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
| 2022-02-24 | Bestätigt | Citigroup | Buy |
| 2022-02-24 | Bestätigt | Cowen | Outperform |
| 2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-24 | Bestätigt | SVB Leerink | Outperform |
| 2022-02-24 | Bestätigt | Stifel | Buy |
| 2022-02-24 | Bestätigt | Wells Fargo | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-11 | Eingeleitet | Stifel | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-06-12 | Eingeleitet | BTIG Research | Buy |
| 2020-02-21 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
Quest Diagnostics Expands Preventive Reach With Shield Colorectal Blood Test - simplywall.st
Capital International Investors Sells 287,217 Shares of Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Guardant Health at Leerink Global Healthcare: Strategic Growth and Partnerships - Investing.com Canada
Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics - National Today
Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics - Yahoo Finance
Hidalgo Medina sells Guardant Health (GH) shares for $118,996 By Investing.com - Investing.com India
Hidalgo Medina sells Guardant Health (GH) shares for $118,996 - Investing.com
Guardant Health (NASDAQ:GH) Director Medina Manuel Hidalgo Sells 1,300 Shares - MarketBeat
Victory Capital Management Inc. Cuts Stake in Guardant Health, Inc. $GH - MarketBeat
Rhenman & Partners Asset Management AB Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
How geopolitical risks impact Guardant Health Inc. (5GH) stockWeekly Trade Recap & Fast Exit/Entry Strategy Plans - Naître et grandir
Guardant Health Tour Highlights Colorectal Test Uptake And Valuation Gap - Yahoo Finance
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now? - Finviz
TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth? - Yahoo Finance
Legato Capital Management LLC Has $677,000 Position in Guardant Health, Inc. $GH - MarketBeat
Amova Asset Management Americas Inc. Has $47.12 Million Position in Guardant Health, Inc. $GH - MarketBeat
ARK Investment Management LLC Sells 2,028,263 Shares of Guardant Health, Inc. $GH - MarketBeat
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and 908 Devices (MASS) - The Globe and Mail
Guardant Health Targets Early Detection Growth With New Partner And Acquisition - simplywall.st
Shield mobile tour brings FDA-approved screening to 100 communities, Guardant Health announces - Traders Union
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America - Guardant Health
Segall Bryant & Hamill LLC Increases Stock Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing - GuruFocus
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened - Guardant Health
GH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Intech Investment Management LLC Has $3.19 Million Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
TD Asset Management Boosts Guardant Health Holdings - National Today
Guardant Health (GH) director acquires 154 shares via RSU vesting - Stock Titan
Guardant Health, Inc. (GH) Stock Analysis: A 41% Upside Potential With Strong Buy Ratings - DirectorsTalk Interviews
Does Guardant’s 2026 Outlook And Shelf Filing Reshape The Bull Case For Guardant Health (GH)? - simplywall.st
TD Asset Management Inc Boosts Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Strengthens Health Technology Portfolio with MetaSight Diagnostics Acquisition - Bitget
TD Cowen Health Care Conference - marketscreener.com
Guardant Health (GH) Is Down 8.9% After Issuing 2026 Guidance And New Equity Shelf Registration – Has The Bull Case Changed? - Yahoo Finance
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know - The Globe and Mail
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
Erste Asset Management GmbH Buys 66,617 Shares of Guardant Health, Inc. $GH - MarketBeat
Colon cancer screening expands with simple blood test as cases rise among under-50s - WLUK
Guardant Health (GH) Gained from Better-Than-Expected Results - Insider Monkey
Guardant Health Stock Hits Day Low at $94.62 Amid Price Pressure - Markets Mojo
Guardant Health, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:GH) 2026-02-25 - Seeking Alpha
Guardant Health Stock Hits Day Low of $93.79 Amid Price Pressure - Markets Mojo
Single‑Reference Disclosures and the Motivation‑to‑Combine Requirement - The National Law Review
Liquidity Mapping Around (GH) Price Events - Stock Traders Daily
Piper Sandler Raises Guardant Health (GH) Price Target to $130 | - GuruFocus
Vanguard Group Inc. Reduces Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health acquires Israeli healthtech MetaSight for up to $150M - MSN
Guardant Health pushes for AI-driven oncology breakthroughs at Cancer 2035 - Traders Union
Guardant Health slides as investors digest Q4 results and a risk-off tape - Quiver Quantitative
Guardant Health, Inc. (GH) Stock Analysis: A 26.53% Upside Potential in the Precision Oncology Market - DirectorsTalk Interviews
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):